Gastrointestinal Cancer
Paclitaxel w/wo Ramucirumab in Metastatic Gastric Cancer (UW10036)
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine
Investigator: Edward Lin, MD; Conditions: Gastric Cancer; Status: Closed; Study ID: NCT01170663
A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for subjects with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib and sunitinib
Investigator: Robin Jones; Conditions: Gastrointestinal Cancer; Status: Closed; Study ID: NCT01271712
Join Us On